Jenna Dilkes | Associate Director – Planning & Operations, Medicines Evaluation
NICE

Jenna Dilkes, Associate Director – Planning & Operations, Medicines Evaluation, NICE

Jenna is an experienced health technology assessment and operations professional with over 14 years at the National Institute for Health and Care Excellence (NICE). Throughout her career at NICE, Jenna has held a range of progressively senior roles across the Technology Appraisals and Highly Specialised Technologies (HST) programmes, developing extensive expertise in programme management, operational planning, stakeholder coordination, and the delivery of complex HTA processes.
Currently serving as Associate Director – Planning & Operations for Medicines Evaluation, Jenna leads strategic operational planning and programme delivery activities supporting some of NICE’s most high-profile appraisal programmes. Prior to this, she held Programme Manager and Project Manager positions within the Technology Appraisals and HST teams, where she played a key role in managing appraisal timelines, coordinating cross-functional stakeholders, and supporting the efficient delivery of health technology evaluations. Jenna began her career at NICE in administrative and public involvement roles, providing her with a strong foundation in stakeholder engagement and programme operations. Her broad experience across multiple areas of NICE has given her a deep understanding of HTA processes, governance, and operational delivery within the UK healthcare landscape.

Appearances:



Day 2 - World Orphan Drug Congress USA 2026 @ 12:40

Panel: From Designation to Decision: Fast Tracking UK, Ireland & EU Access for Orphan Medicines

Despite regulatory incentives and strong scientific innovation, orphan medicines are still frequently launched late,  or not at all,  in the UK, Ireland and parts of the EU. Smaller populations, complex HTA requirements and uncertainty around evidence expectations can push these markets down the launch sequence. This panel will examine how developers can de‑risk access decisions earlier, by aligning evidence generation across regulators, HTA bodies, payers and patient organisations. Drawing on perspectives from patient advocacy, policy and industry, the discussion will focus on what really moves the needle, from early scientific advice and patient‑relevant endpoints through to managed access agreements and reimbursement decisions.

last published: 01/Jun/26 09:55 GMT

back to speakers

Get Involved At World Orphan Drug Congress USA

 

Connect with us

 
 
 

 

To Sponsor Or Exhibit

 
 

Jack Rendell
jack.rendell@terrapinn.com
t/ +44 07577689029

 

 

 

To Speak

 
 

Abdu Kauroo
abdu.kauroo@terrapinn.com
 

 

 

 

Marketing & Press

 
 

Jasper Cameron
jasper.cameron@terrapinn.com